查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球双相情感障碍市场（2022-2028）：按药物类别（情绪稳定剂、抗惊厥药）和类型（双相 I 型障碍、双相 II 型障碍）分列的规模、份额、增长分析和预测
市场调查报告书
商品编码
1244243

全球双相情感障碍市场（2022-2028）：按药物类别（情绪稳定剂、抗惊厥药）和类型（双相 I 型障碍、双相 II 型障碍）分列的规模、份额、增长分析和预测

Global Bipolar Disorder Market Size, Share, Growth Analysis, By Drug Class(Mood Stabilizers, Anticonvulsants), By Type(Bipolar I Disorder, Bipolar II Disorder) - Industry Forecast 2022-2028
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球躁郁症市场规模预计将从 2021 年的 53 亿美元增长到 2028 年的 61 亿美元，预测期内的复合年增长率超过 2.12%。.

近年来双相情感障碍的全球患病率一直在上升，推动了市场的增长。 据世界卫生组织称，双相情感障碍是全球第六大残疾原因，全世界估计有 6000 万人受到影响。 双相情感障碍患病率的增加归因于生活方式改变、压力水平增加和遗传等因素。

在本报告中，我们研究了全球双相情感障碍市场，提供了市场概况、对市场的各种影响因素的分析、技术和创新趋势、市场规模的趋势和预测，以及各个细分市场和细分市场的细分地区、竞争格局、主要公司概况等。

内容

执行摘要

市场概览

母市场分析

市场概览

市场规模

  • 市场动态
  • 司机
  • 机会
  • 约束因素
  • 任务
  • SWOT 分析

主要市场洞察

  • 技术分析
  • 价格分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 知识产权分析
  • 贸易分析
  • 启动分析
  • 原材料分析
  • 创新矩阵
  • 管道产品分析
  • 宏观经济指标

COVID-19 的影响

市场动态和前景

  • 市场动态
  • 司机
  • 机会
  • 约束因素
  • 任务
  • 监管状况
  • SWOT 分析
  • 波特的分析
  • Skyquest 对未来颠覆的特别洞察
  • 全球双相情感障碍市场：按药物分类
  • 情绪稳定剂
  • 抗惊厥药
  • 抗精神病药
  • 抗抑郁药
  • 抗焦虑药
  • 其他

全球双相情感障碍市场：按类型分类

  • I型双相情感障碍
  • 双相 II 型障碍
  • 循环障碍
  • 其他

按地区划分的市场规模

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

主要公司简介

  • 竞争格局
  • Allergan
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Abbott
  • Bristol-Myers Squibb
  • Johnson &Johnson
  • Pfizer Inc.
  • Cephalon Inc.
  • Otsuka America Pharmaceutical Inc.
  • Gedeon Richter plc
简介目录
Product Code: SQSG45I2027

Global Bipolar Disorder Market was valued at USD 5.3 Billion in 2021, and it is expected to reach a value of USD 6.1 Billion by 2028, at a CAGR of more than 2.12% over the forecast period (2022-2028).

The global bipolar disorder market refers to the market for pharmaceuticals and treatment options used to manage bipolar disorder, which is a mental health condition characterized by episodes of depression and mania. The market for bipolar disorder treatment is driven by several factors, including the increasing prevalence of the disorder, growing awareness and diagnosis of the condition, and the introduction of new and innovative treatment options. The market includes a wide range of products such as mood stabilizers, antipsychotics, antidepressants, and psychotherapy.

Top-down and bottom-up approaches were used to estimate and validate the size of Global Bipolar Disorder Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

Global bipolar disorder market is segmented based on the drug class, type, and region. Based on the drug class, the global bipolar disorder market is segmented as mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressant drugs, antianxiety drugs and others. Based on type, the global bipolar disorder market is segmented as, bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Based on region, it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

The global prevalence of bipolar disorder has been increasing in recent years, which is driving the growth of the bipolar disorder market. According to the World Health Organization, bipolar disorder is the sixth leading cause of disability worldwide, affecting an estimated 60 million people globally. The increasing prevalence of bipolar disorder is attributed to factors such as changing lifestyles, increasing stress levels, and genetic factors.

Restraint

Despite significant advances in the diagnosis and treatment of the bipolar disorder, the underlying causes of the condition are not yet fully understood. This can limit the development of effective treatments and make it more challenging to identify patients who are at risk of developing bipolar disorder.

Market Trends

Personalized medicine is an emerging trend in the bipolar disorder market, with a growing focus on developing targeted therapies that address the specific needs of individual patients. Advances in genetics and biomarker research are helping to identify subtypes of bipolar disorder, which could lead to more effective and personalized treatments. Additionally, the development of digital health tools, such as mobile apps and wearables, is enabling the collection of real-time patient data that can be used to inform personalized treatment plans. As the demand for personalized medicine continues to grow, we can expect to see more investment in research and development of targeted therapies for bipolar disorder.

Table of Contents

Executive Summary

Market overview

  • Exhibit: Executive Summary - Chart on Market Overview
  • Exhibit: Executive Summary - Data Table on Market Overview
  • Exhibit: Executive Summary - Chart on Global Global Bipolar Disorder Market Characteristics
  • Exhibit: Executive Summary - Chart on Market by Geography
  • Exhibit: Executive Summary - Chart on Market Segmentation
  • Exhibit: Executive Summary - Chart on Incremental Growth
  • Exhibit: Executive Summary - Data Table on Incremental Growth
  • Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy-scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Global Bipolar Disorder Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
  • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
  • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
  • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
  • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
  • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact
  • Global Global Bipolar Disorder Market by Drug Class
  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Mood Stabilizers
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Anticonvulsants
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Antipsychotic Drugs
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Antidepressant Drugs
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Antianxiety Drugs
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Other
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

Global Global Bipolar Disorder Market by Type

  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Bipolar I Disorder
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Bipolar II Disorder
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Cyclothymic Disorder
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Others
    • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
  • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
  • Exhibit: company positioning matrix, 2021
    • Top companies market Share
  • Exhibit: Pie chart analysis on company market share, 2021(%)
  • Allergan (Ireland)AstraZeneca (UK)Eli Lilly and Company (US)GlaxoSmithKline (UK)Abbott (US)Bristol-Myers Squibb (US)Johnson & Johnson (US)Pfizer Inc. (US)Cephalon Inc. (US)Otsuka America Pharmaceutical Inc. (US)Gedeon Richter plc (Hungary)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Allergan (Ireland)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • AstraZeneca (UK)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Eli Lilly and Company (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • GlaxoSmithKline (UK)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Abbott (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Bristol-Myers Squibb (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Johnson & Johnson (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Pfizer Inc. (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cephalon Inc. (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Otsuka America Pharmaceutical Inc. (US)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Gedeon Richter plc (Hungary)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments